<DOC>
	<DOCNO>NCT02249676</DOCNO>
	<brief_summary>Neuromyelitis optica ( NMO ) demyelinate degenerative disorder central nervous system affect vision brain spinal cord function lead accumulate disability 5 year-mortality approximately 30 % . Survivors typically leave severe morbidity secondary blindness , quadriparesis respiratory failure . No agent find highly effective halt disease activity.Based recent outcome Multipotent mesenchymal stromal cell autoimmune disease include multiple sclerosis , base mechanism neuromyelitis optica , investigator anticipate mesenchymal stem cell transplantation may provide last disease stability neuromyelitis optica patient .</brief_summary>
	<brief_title>Autologous Mesenchymal Stem Cells Treatment Neuromyelitis Optica Spectrum Disorders</brief_title>
	<detailed_description>Primary objective ass feasibility safety ; investigator compare adverse event 3months treatment 12 month infusion . As secondary objective , investigator choose efficacy outcome assess Expanded Disability Status ( EDSS ) „ÄÅannual relapse rate ( ARR ) time next relapse transplant . Third objective anterior visual pathway pyramidal tract model wider disease . Masked endpoint analysis use electrophysiological select image outcome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>Clinically definite neuromyelitis optica neuromyelitis optica spectrum disorder Age &gt; 18 year EDSS &gt; 3 Progression continue relapse worsen MRI least year attempt therapy evidence one following : Increase 1 EDSS point ( baseline EDSS &lt; 5.0 ) 0.5 EDSS point ( baseline EDSS &gt; 5.5 ) Moderatesevere relapse past 18 month Gadolinium enhance lesion ( double triple dose Gd ) 1 new T2 lesion Evidence recent inflammatory disease , evidence one following : 1 moderatesevere relapse past 18 month 1 Gdenhancing lesion ( single , double triple dose Gd ) 1 new T2 lesion Received Immune inhibitor immunomodulator three month trial Significant cardiac , renal , hepatic failure disease may affect result study Allergies Pregnant possibly pregnant Cognitive decline understand sign inform consent Brain tumor , HIV ( + ) tumor marker ( + ) , blood pressure ( BP ) : 200 /110 mmHg Judged suitable doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Autologous mesenchymal stem cell</keyword>
	<keyword>neuromyelitis optica</keyword>
	<keyword>treatment</keyword>
</DOC>